APGE

SEC source: 0001104659-25-000956 · tm251928-1_4seq1.xml · nonDerivative · entry 4

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 255,348

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

SEC source: 0001104659-25-000956 · tm251928-1_4seq1.xml · nonDerivative · entry 3

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 255,448

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.88 to $47.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-000956 · tm251928-1_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 257,934

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.87 to $46.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-000956 · tm251928-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 259,433

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-24-128588 · tm2430955-2_4seq1.xml · nonDerivative · entry 2

McKenna Mark C. · CIK 0001749623 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

F2 · price: The price reported above is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $49.6275 to $50.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001104659-24-128588 · tm2430955-2_4seq1.xml · nonDerivative · entry 1

McKenna Mark C. · CIK 0001749623 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

F1 · price: The price reported above is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $48.50 to $49.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001104659-24-128559 · tm2430955-1_4seq1.xml · derivative · entry 4

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,530

Underlying: Common Stock · 1,815 shares

Expires 2033-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-24-128559 · tm2430955-1_4seq1.xml · nonDerivative · entry 3

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 258,073

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

SEC source: 0001104659-24-128559 · tm2430955-1_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 258,528

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

SEC source: 0001104659-24-128559 · tm2430955-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 262,613

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-24-127705 · tm2430773-2_4seq1.xml · derivative · entry 1

Henderson Jane · CIK 0001422304 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,962

Underlying: Common Stock · 124,962 shares

Expires 2034-12-09

F1 · derivative.exercise_date: This option represents the right to purchase 124,962 shares of the Issuer's common stock, and will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-24-127707 · tm2430773-3_4seq1.xml · derivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 357,036

Underlying: Common Stock · 357,036 shares

Expires 2034-12-09

F1 · derivative.exercise_date: This option represents the right to purchase 357,036 shares of the Issuer's common stock, and will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-24-127704 · tm2430773-1_4seq1.xml · derivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,962

Underlying: Common Stock · 124,962 shares

Expires 2034-12-09

F1 · derivative.exercise_date: This option represents the right to purchase 124,962 shares of the Issuer's common stock, and will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-24-126394 · tm2430233-2_4seq1.xml · nonDerivative · entry 2

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,324,487

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.00 to $47.275, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-126394 · tm2430233-2_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,326,159

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.00 to $46.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-126395 · tm2430233-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 260,798

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

SEC source: 0001104659-24-116024 · tm2427837-2_4seq1.xml · nonDerivative · entry 2

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,339,487

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

SEC source: 0001104659-24-116024 · tm2427837-2_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,340,487

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.69 to $59.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-116027 · tm2427837-1_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 267,463

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.55 to $60.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-116027 · tm2427837-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 268,802

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.50 to $59.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-106364 · tm2425574-2_4seq1.xml · nonDerivative · entry 2

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,354,487

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.52 to $57.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-106364 · tm2425574-2_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,364,199

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.51 to $56.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-106367 · tm2425574-1_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 274,128

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.64 to $57.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-106367 · tm2425574-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 275,053

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.62 to $56.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-097866 · tm2423502-1_4seq1.xml · nonDerivative · entry 2

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,394,487

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.95 to $48.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-097866 · tm2423502-1_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,408,846

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.95 to $47.855, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-097867 · tm2423502-2_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 280,793

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.80 to $48.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-097867 · tm2423502-2_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 281,580

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.79 to $47.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-092519 · tm2422592-1_4seq1.xml · nonDerivative · entry 1

Henderson Jane · CIK 0001422304 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,871

SEC source: 0001104659-24-087939 · tm2421174-1_4seq1.xml · nonDerivative · entry 3

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,434,487

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

SEC source: 0001104659-24-087939 · tm2421174-1_4seq1.xml · nonDerivative · entry 2

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,434,587

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.15 to $42.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range

SEC source: 0001104659-24-087939 · tm2421174-1_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,442,254

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-087940 · tm2421174-2_4seq1.xml · nonDerivative · entry 3

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 287,458

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

SEC source: 0001104659-24-087940 · tm2421174-2_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 288,128

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.08 to $41.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-087940 · tm2421174-2_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 288,270

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-078135 · tm2418983-2_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,474,487

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.78 to $37.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-078134 · tm2418983-1_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 294,793

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.85 to $38.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-078134 · tm2418983-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 296,936

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.80 to $37.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-24-069793 · tm2416491-2_4seq1.xml · derivative · entry 1

Shah Nimish P · CIK 0001698082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,370

Underlying: Common Stock · 10,370 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

F2 · ownership.direct: Under an agreement between the Reporting Person and VR Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

SEC source: 0001104659-24-069803 · tm2416491-4_4seq1.xml · derivative · entry 1

JONES WILLIAM A JR · CIK 0001373097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,370

Underlying: Common Stock · 10,370 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

SEC source: 0001104659-24-069790 · tm2416491-7_4seq1.xml · derivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,370

Underlying: Common Stock · 10,370 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

F3 · ownership.direct: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more Fairmount Funds. Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC source: 0001104659-24-069790 · tm2416491-7_4seq1.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,370

Underlying: Common Stock · 10,370 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

F2 · ownership.direct: Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC source: 0001104659-24-069798 · tm2416491-6_4seq1.xml · derivative · entry 1

McKenna Mark C. · CIK 0001749623 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,370

Underlying: Common Stock · 10,370 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

SEC source: 0001104659-24-069795 · tm2416491-3_4seq1.xml · derivative · entry 1

Fox Jennifer A. · CIK 0001841557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,370

Underlying: Common Stock · 10,370 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

SEC source: 0001104659-24-069792 · tm2416491-1_4seq1.xml · derivative · entry 1

Gottesdiener Andrew · CIK 0001972292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,370

Underlying: Common Stock · 10,370 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

F2 · ownership.direct: Under an agreement between the Reporting Person and VR Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

SEC source: 0001104659-24-069797 · tm2416491-5_4seq1.xml · derivative · entry 1

Bollinger Lisa · CIK 0002024557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,112

Underlying: Common Stock · 8,112 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option represents the right to purchase 8,112 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

SEC source: 0001104659-24-066788 · tm2415914-2_4seq1.xml · derivative · entry 1

Bollinger Lisa · CIK 0002024557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,550

Underlying: Common Stock · 18,550 shares

Expires 2034-05-28

F1 · derivative.exercise_date: This option represents the right to purchase 18,550 shares of the Issuer's common stock, and will vest in three approximately equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · derivative · entry 6

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 6,743,321

Underlying: Common Stock · 6,521,895 shares

Expires not disclosed

F4 · derivative.exercise_price: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F4 · derivative.exercise_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F4 · derivative.expiration_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · derivative · entry 5

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund LP

Disclosed balance after: 0

Underlying: Common Stock · 221,426 shares

Expires not disclosed

F4 · derivative.exercise_price: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F4 · derivative.exercise_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F4 · derivative.expiration_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 2,048,647

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.